Go to
JCI Insight
Citations to this article
Matthew J. Frigault, Marcela V. Maus
Published April 1, 2020
Citation Information: J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208.
Citation Information: J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208.
Abstract
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19+ B cell malignancies, multiple clinical trials of CAR T cell therapy directed to CD19 have led to the approval of this therapy by the FDA and the European Medicines Agency for specific indications. Despite strikingly similar efficacy, investigators at multiple centers participating in these studies have observed the nuances of each CAR T cell product, including variability in manufacturing, availability, and toxicity profiles. Here we review state-of-the-art clinical data on CD19-directed CAR T cell therapies in B cell hematologic malignancies, advances made in understanding and modeling associated toxicities, and several exciting advances and creative solutions for overcoming challenges with this therapeutic modality.
Authors
Matthew J. Frigault, Marcela V. Maus
Citation information
Citations to this article (60)
| Title and authors | Publication | Year |
|---|---|---|
|
Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE
Artur Wilhelm, David Chambers, Fabian Müller, Aline Bozec, Ricardo Grieshaber-Bouyer, Thomas Winkler, Dimitrios Mougiakakos, Andreas Mackensen, Georg Schett, Gerhard Krönke |
JCI Insight | 2024 |
|
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy
Zarezadeh Mehrabadi A, Tat M, Ghorbani Alvanegh A, Roozbahani F, Esmaeili Gouvarchin Ghaleh H |
Frontiers in immunology | 2024 |
|
A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation
Lee HW, O\u2019Reilly C, Beckett AN, Currier DG, Chen T, DeRenzo C |
Journal of experimental & clinical cancer research : CR | 2024 |
|
Immunometabolic adaptation of CD19-targeted CAR T cells in the central nervous system microenvironment of patients promotes memory development
Goldberg L, Haas ER, Urak R, Vyas V, Pathak KV, Garcia-Mansfield K, Pirrotte P, Singhal J, Figarola JL, Aldoss I, Forman SJ, Wang X |
Cancer research | 2024 |
|
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.
Zhang W, Li S, Long J, Xie S, Wang M, Liu H, Xu Z |
Experimental Hematology and Oncology | 2024 |
|
Controlling CAR-T cell activity and specificity with synthetic SparX adapters
Edwards JP, Swers JS, Buonato JM, Zaritskaya L, Mu CJ, Gupta A, Shachar S, LaFleur DW, Richman LK, Tice DA, Hilbert DM |
Molecular Therapy | 2024 |
|
Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells
Qie Y, Gadd ME, Shao Q, To T, Liu A, Li S, Rivera\u2010Valentin R, Yassine F, Murthy HS, Dronca R, Kharfan\u2010Dabaja MA, Qin H, Luo Y |
MedComm | 2024 |
|
A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications
Wiedemann G, Bacher U, Joncourt R, Solly F, Widmer CC, Zeerleder S, Novak U, Pabst T, Porret NA |
International Journal of Molecular Sciences | 2024 |
|
B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates.
Kaminski J, Fleming RA, Alvarez-Calderon F, Winschel MB, McGuckin C, Ho EE, Eng F, Rui X, Keskula P, Cagnin L, Charles J, Zavistaski J, Margossian SP, Kapadia MA, Rottman JB, Lane J, Baumeister SHC, Tkachev V, Shalek AK, Kean LS, Gerdemann U |
Blood | 2024 |
|
Hematologists’ perspective on advance directives, a French national cross-sectional survey – the ADORE-H study
Serey K, Cambriel A, Pollina-Bachellerie A, Bay JO, Bouleuc C, Ladrat L, Lotz JP, Philippart F |
BMC Medical Ethics | 2024 |
|
Single-cell transcriptomics reveals an abnormal immune microenvironment in plasma cell mastitis
Ni Q, Han G, Pan C |
Annals of Medicine | 2024 |
|
scImmOmics: a manually curated resource of single-cell multi-omics immune data
Li YY, Zhou LW, Qian FC, Fang QL, Yu ZM, Cui T, Dong FJ, Cai FH, Yu TT, Li LD, Wang QY, Zhu YB, Tang HF, Hu BY, Li CQ |
Nucleic Acids Research | 2024 |
|
Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR
Chen X, Chen LC, Khericha M, Meng X, Salvestrini E, Shafer A, Iyer N, Alag AS, Ding Y, Nicolaou DM, Chen YY |
Cancer immunology research | 2023 |
|
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects
Al-Ibraheem A, Abdlkadir AS, Juweid ME, Al-Rabi K, Ma\u2019koseh M, Abdel-Razeq H, Mansour A |
Cancers | 2023 |
|
CD47 expression is critical for CAR T-cell survival in vivo
Beckett AN, Chockley P, Pruett-Miller SM, Nguyen P, Vogel P, Sheppard H, Krenciute G, Gottschalk S, DeRenzo C |
Journal for ImmunoTherapy of Cancer | 2023 |
|
A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group.
Worel N, Holbro A, Vrielink H, Ootjers C, Le Poole K, Beer-Wekking I, Rintala T, Lozano M, Bonig H |
Bone Marrow Transplantation | 2023 |
|
Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies
Bhattacharyya P, Christopherson RI, Skarratt KK, Chen JZ, Balle T, Fuller SJ |
Cancers | 2023 |
|
Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells
Wang S, Wei W, Yuan Y, Sun B, Yang D, Liu N, Zhao X |
Journal of Translational Medicine | 2023 |
|
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
Lee EH, Murad JP, Christian L, Gibson J, Yamaguchi Y, Cullen C, Gumber D, Park AK, Young C, Monroy I, Yang J, Stern LA, Adkins LN, Dhapola G, Gittins B, Chang WC, Martinez C, Woo Y, Cristea M, Rodriguez-Rodriguez L, Ishihara J, Lee JK, Forman SJ, Wang LD, Priceman SJ |
Nature Communications | 2023 |
|
Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel
Leone G, Baldini V, Bramanti S, Crocchiolo R, Gattillo S, Ermini S, Giudice V, Ferrero I, Moscato T, Milani R, Gozzer M, Piccirillo N, Tassi C, Tassi V, Coluccia P |
Blood Transfusion | 2023 |
|
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Pfeifer BA, Beitelshees M, Hill A, Bassett J, Jones CH |
npj Systems Biology and Applications | 2023 |
|
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
J Meier, B Savoldo, N Grover |
Journal of Personalized Medicine | 2022 |
|
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
N Hebbar, R Epperly, A Vaidya, U Thanekar, S Moore, M Umeda, J Ma, S Patil, D Langfitt, S Huang, C Cheng, J Klco, S Gottschalk, M Velasquez |
Nature Communications | 2022 |
|
SILAC Phosphoproteomics Reveals Unique Signaling Circuits in CAR-T Cells and the Inhibition of B Cell-Activating Phosphorylation in Target Cells
A Griffith, K Callahan, N King, Q Xiao, X Su, A Salomon |
Journal of Proteome Research | 2022 |
|
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma
W Lei, Q Ye, Y Hao, J Chen, Y Huang, L Yang, S Wang, W Qian |
Blood Cancer Journal | 2022 |
|
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
B Blanco, Á Ramírez-Fernández, C Bueno, L Argemí-Muntadas, P Fuentes, Ó Aguilar-Sopeña, F Gutierrez-Agüera, S Zanetti, A Tapia-Galisteo, L Díez-Alonso, A Segura-Tudela, M Castellà, B Marzal, S Betriu, S Harwood, M Compte, S Lykkemark, A Erce-Llamazares, L Rubio-Pérez, A Jiménez-Reinoso, C Domínguez-Alonso, M Neves, P Morales, E Paz-Artal, S Guedan, L Sanz, M Toribio, P Roda-Navarro, M Juan, P Menéndez, L Álvarez-Vallina |
Cancer immunology research | 2022 |
|
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo M, Nastasi C |
Frontiers in Oncology | 2022 |
|
CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.
Tan JY, Low MH, Chen Y, Lim FLWI |
International journal of molecular sciences | 2022 |
|
CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
Su L, Wu L, Lobb RR, Rennert PD, Ambrose C |
OncoImmunology | 2022 |
|
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells.
Caël B, Galaine J, Bardey I, Marton C, Fredon M, Biichle S, Poussard M, Godet Y, Angelot-Delettre F, Barisien C, Bésiers C, Adotevi O, Pouthier F, Garnache-Ottou F, Bôle-Richard E |
Cancers | 2022 |
|
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM |
Therapeutic advances in medical oncology | 2022 |
|
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Sterner RC, Sterner RM |
Frontiers in immunology | 2022 |
|
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
Gehlert CL, Rahmati P, Boje AS, Winterberg D, Krohn S, Theocharis T, Cappuzzello E, Lux A, Nimmerjahn F, Ludwig RJ, Lustig M, Rösner T, Valerius T, Schewe DM, Kellner C, Klausz K, Peipp M |
Frontiers in immunology | 2022 |
|
Emerging Trends in Immunotherapy for Cancer
Mishra AK, Ali A, Dutta S, Banday S, Malonia SK |
Diseases | 2022 |
|
The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.
Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, Li Z, Ni R, Li L, Su H, Liu Y |
Frontiers in pharmacology | 2022 |
|
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Plocque A, Mitri C, Lefèvre C, Tabary O, Touqui L, Philippart F |
Drugs | 2022 |
|
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
Berger SC, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk FA |
Haematologica | 2022 |
|
Nanomedicines in B Cell-Targeting Therapies
J Wang, J Yang, J Kopeček |
Acta Biomaterialia | 2021 |
|
Engineering living therapeutics with synthetic biology
A Cubillos-Ruiz, T Guo, A Sokolovska, PF Miller, JJ Collins, TK Lu, JM Lora |
Nature Reviews Drug Discovery | 2021 |
|
Current Treatment Options in CLL
M Bewarder, S Stilgenbauer, L Thurner, D Kaddu-Mulindwa |
Cancers | 2021 |
|
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
DG Tantalo, AJ Oliver, B von Scheidt, AJ Harrison, SN Mueller, MH Kershaw, CY Slaney |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Tumor-associated myeloid cells: diversity and therapeutic targeting
A Mantovani, F Marchesi, S Jaillon, C Garlanda, P Allavena |
Cellular and Molecular Immunology | 2021 |
|
Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse
S Faude, J Wei, K Muralidharan, X Xu, G Wertheim, M Paessler, VG Bhoj, SA Grupp, SL Maude, SR Rheingold, V Pillai |
Blood Advances | 2021 |
|
The potential of CAR T cell therapy for prostate cancer
P Wolf, J Alzubi, C Gratzke, T Cathomen |
Nature Reviews Urology | 2021 |
|
Using Adoptive Cellular Therapy for Localized Protein Secretion
AN Evans, HK Lin, AK Hossian, S Rafiq |
Cancer journal (Sudbury, Mass.) | 2021 |
|
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
JP Heidbuechel, CE Engeland |
Journal of Hematology & Oncology | 2021 |
|
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
B Casadei, L Argnani, S Guadagnuolo, C Pellegrini, V Stefoni, A Broccoli, L Nanni, A Morigi, G Lolli, M Guarino, L Spinardi, E Pierucci, S Fanti, M Bartoletti, M Dicataldo, E Sabattini, F Bonifazi, PL Zinzani |
Cancers | 2021 |
|
Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells
H Fujiwara |
International Journal of Hematology | 2021 |
|
Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials
Y Zhang, A Sharma, H Weiher, M Schmid, G Kristiansen, IG Schmidt-Wolf |
Cancers | 2021 |
|
Liquid biopsy in lymphoma: Is it primed for clinical translation?
Poynton E, Okosun J |
2021 | |
|
Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo.
Rennert PD, Dufort FJ, Su L, Sanford T, Birt A, Wu L, Lobb RR, Ambrose C |
Molecular cancer therapeutics | 2021 |
|
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities
Chiara F. Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Giada Matera, Benedetta Cabiati, Chiara Buracchi, Gianmaria Borleri, Grazia Fazio, Silvia Zaninelli, Sarah Tettamanti, Stefania Cesana, Valentina Colombo, Michele Quaroni, Giovanni Cazzaniga, Attilio Rovelli, Ettore Biagi, Stefania Galimberti, Andrea Calabria, Fabrizio Benedicenti, Eugenio Montini, Silvia Ferrari, Martino Introna, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi |
Journal of Clinical Investigation | 2020 |
|
Immunotherapy of multiple myeloma
Simone A. Minnie, Geoffrey R Hill |
Journal of Clinical Investigation | 2020 |
|
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
M Unterrainer, M Ruzicka, MP Fabritius, LM Mittlmeier, M Winkelmann, J Rübenthaler, M Brendel, M Subklewe, M von Bergwelt-Baildon, J Ricke, WG Kunz, CC Cyran |
2020 | |
|
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
CF Magnani, S Tettamanti, G Alberti, I Pisani, A Biondi, M Serafini, G Gaipa |
Cells | 2020 |
|
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
MJ Frigault, S Nikiforow, MK Mansour, ZH Hu, MM Horowitz, ML Riches, P Hematti, CJ Turtle, MJ Zhang, MA Perales, MC Pasquini |
Blood | 2020 |
|
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
S Roßkopf, KM Eichholz, D Winterberg, KJ Diemer, S Lutz, IA Münnich, K Klausz, T Rösner, T Valerius, DM Schewe, A Humpe, M Gramatzki, M Peipp, C Kellner |
Antibodies | 2020 |
|
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
Feucht J, Sadelain M |
2020 | |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)